A prospective, randomized, double-blinded, placebo-controlled, cross-over study investigating the effects of metyrapone treatment on cardio-metabolic outcome parameters and chronobiology in patients with mild autonomous cortisol secretion

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526837-24-00

Enrollment

Registered

2026-08-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild autonomous cortisol secretion

Brief summary

Hepatic lipid content

Detailed description

insulin sensitivity (HOMA-IR, OGIS);insulin secretion (Insulinogenic Index);ambulatory systolic and diastolic blood pressure (mean of 5 measurements during 10 minutes in supine position);parameters of systemic inflammation (leukocyte count, neutrophil count, lymphocyte count, monocyte count; leucocyte /neutrophile ratio, leucocyte / lymphocyte ratio)

Interventions

DRUGMetycor 250 mg Weichkapseln

DRUGHydrocortison 10 mg JENAPHARM

DRUGPlacebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Hepatic lipid content	—

Secondary

Measure	Time frame
insulin sensitivity (HOMA-IR, OGIS);insulin secretion (Insulinogenic Index);ambulatory systolic and diastolic blood pressure (mean of 5 measurements during 10 minutes in supine position);parameters of systemic inflammation (leukocyte count, neutrophil count, lymphocyte count, monocyte count; leucocyte /neutrophile ratio, leucocyte / lymphocyte ratio)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 30, 2026